FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551930064> ?p ?o ?g. }

• W2551930064 abstract "Abstract Abstract 3838 Poster Board III-774 Hypoxia is known to be linked to increased metastatic potential and a treatment-resistant phenotype leading to rapid progression and poor prognosis in solid tumors. We confirmed previous data[1] on hypoxia in human multiple myeloma (MM) in the 5T33MM syngeneic murine model of MM by using H&E staining and Hypoxyprobe (Pimonidazole) staining on consecutive serial sections from both naive mice and 5T33MMvv diseased mice. We observed a physiological hypoxic situation in MM diseased bone marrow. Given the contribution of hypoxia to tumor progression and drug resistance, a number of hypoxia-targeted therapeutics are under development. TH-302 is a new hypoxia-activated prodrug (HAP) that is currently being evaluated in the clinical trials as monotherapy and in combination with standard chemotherapy regimens for the treatment of solid tumors. The aims of the current study are (1) to demonstrate the effects of TH302 on MM cells in hypoxic conditions, focusing on apoptosis and cell cycle and associated signaling pathways and (2) to evaluate potential therapeutic effects when used in an experimental mouse MM model. We evaluated the effects of TH-302 in vitro on the murine 5T33MMvt cell line and the human LP-1, MMS-1, RPMI-8226, Karpas MM cell lines. Flow cytometry analysis revealed that TH-302 (0.5-50μM) can induce significant Go/G1 cell cycle phase arrest and apoptosis in hypoxic conditions (both 1% and 0% O2) in a concentration dependent manner, in contrast to normoxic conditions (20% O2) (p<0.001). Western blot confirmed that treatment with TH-302 in hypoxic conditions down-regulates cyclin D1/2/3, CDK4/6 and pRb expressions, but CDK2 expression was not disturbed. Furthermore, treatment with TH-302 in hypoxic conditions down-regulates the anti-apoptotic proteins BCL-2 and BCL-xL, as well as up-regulates the expression of three proapoptotic proteins: cleaved caspase-3, 9 and PARP. The expression pattern of Bax was however not influenced. The expression of p21 and p27 decreased in hypoxic condition after treatment with TH-302. Further studies conducted in the 5T33MMvv mouse model demonstrated that animals treated prophylactically with TH-302 (12.5 mg/kg, 25 mg/kg and 50 mg/kg, i.p.) for 3 weeks from day 1 after tumor inoculation showed decreased serum paraprotein (12.5 mg/kg, 32% decrease, p<0.05; 25 mg/kg, 77% decrease, p<0.001; 50 mg/kg, 54% decrease, p<0.001), compared to vehicle-treated 5T33MMvv mice (n=10). The frequency of apoptotic multiple myeloma cells in bone marrow sections was also significantly increased (12.5 mg/kg, 2.5 fold, p<0.05; 25mg/kg, 2.1 fold, p<0.05; 50mg/kg, 3.1 fold, p<0.01). Treatment with TH-302 resulted in no adverse events, any observable detriment to the mice or weight loss (p>0.05). In conclusion, these results show that hypoxia-activated treatment with TH-302 activates apoptosis and induces cell cycle arrest in MM cells, under hypoxic conditions, both in vitro and in vivo and therefore represents a promising therapeutic approach for multiple myeloma. Reference [1] Simona Colla, Paola Storti, Gaetano Donofrio, et al. Hypoxia and Hypoxia Inducible Factor (HIF)-1α in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment, 50th ASH annual meeting, http://ash.confex.com/ash/2008/webprogram/Paper13156.html Disclosures: Handisides: Treshold Pharmaceuticals: Employment. Liu:Treshold Pharmaceuticals: Employment. Sun:Treshold Pharmaceuticals: Employment. Hart:Treshold Pharmaceuticals: Employment. Vanderkerken:Treshold Pharmaceuticals: Research Funding." @default.
• W2551930064 created "2016-11-30" @default.
• W2551930064 creator A5000510528 @default.
• W2551930064 creator A5003658156 @default.
• W2551930064 creator A5003841688 @default.
• W2551930064 creator A5012653817 @default.
• W2551930064 creator A5014026887 @default.
• W2551930064 creator A5036023565 @default.
• W2551930064 creator A5042870042 @default.
• W2551930064 creator A5051698029 @default.
• W2551930064 creator A5053222814 @default.
• W2551930064 creator A5069551543 @default.
• W2551930064 creator A5074728272 @default.
• W2551930064 date "2009-11-20" @default.
• W2551930064 modified "2023-09-26" @default.
• W2551930064 title "Hypoxia Activated Prodrug TH-302 for the Treatment of Multiple Myeloma." @default.
• W2551930064 doi "https://doi.org/10.1182/blood.v114.22.3838.3838" @default.
• W2551930064 hasPublicationYear "2009" @default.
• W2551930064 type Work @default.
• W2551930064 sameAs 2551930064 @default.
• W2551930064 citedByCount "2" @default.
• W2551930064 countsByYear W25519300642013 @default.
• W2551930064 countsByYear W25519300642014 @default.
• W2551930064 crossrefType "journal-article" @default.
• W2551930064 hasAuthorship W2551930064A5000510528 @default.
• W2551930064 hasAuthorship W2551930064A5003658156 @default.
• W2551930064 hasAuthorship W2551930064A5003841688 @default.
• W2551930064 hasAuthorship W2551930064A5012653817 @default.
• W2551930064 hasAuthorship W2551930064A5014026887 @default.
• W2551930064 hasAuthorship W2551930064A5036023565 @default.
• W2551930064 hasAuthorship W2551930064A5042870042 @default.
• W2551930064 hasAuthorship W2551930064A5051698029 @default.
• W2551930064 hasAuthorship W2551930064A5053222814 @default.
• W2551930064 hasAuthorship W2551930064A5069551543 @default.
• W2551930064 hasAuthorship W2551930064A5074728272 @default.
• W2551930064 hasConcept C108215921 @default.
• W2551930064 hasConcept C126322002 @default.
• W2551930064 hasConcept C150903083 @default.
• W2551930064 hasConcept C178790620 @default.
• W2551930064 hasConcept C185592680 @default.
• W2551930064 hasConcept C190283241 @default.
• W2551930064 hasConcept C207001950 @default.
• W2551930064 hasConcept C2776364478 @default.
• W2551930064 hasConcept C2780007613 @default.
• W2551930064 hasConcept C502942594 @default.
• W2551930064 hasConcept C540031477 @default.
• W2551930064 hasConcept C55493867 @default.
• W2551930064 hasConcept C71924100 @default.
• W2551930064 hasConcept C7836513 @default.
• W2551930064 hasConcept C86803240 @default.
• W2551930064 hasConcept C98274493 @default.
• W2551930064 hasConceptScore W2551930064C108215921 @default.
• W2551930064 hasConceptScore W2551930064C126322002 @default.
• W2551930064 hasConceptScore W2551930064C150903083 @default.
• W2551930064 hasConceptScore W2551930064C178790620 @default.
• W2551930064 hasConceptScore W2551930064C185592680 @default.
• W2551930064 hasConceptScore W2551930064C190283241 @default.
• W2551930064 hasConceptScore W2551930064C207001950 @default.
• W2551930064 hasConceptScore W2551930064C2776364478 @default.
• W2551930064 hasConceptScore W2551930064C2780007613 @default.
• W2551930064 hasConceptScore W2551930064C502942594 @default.
• W2551930064 hasConceptScore W2551930064C540031477 @default.
• W2551930064 hasConceptScore W2551930064C55493867 @default.
• W2551930064 hasConceptScore W2551930064C71924100 @default.
• W2551930064 hasConceptScore W2551930064C7836513 @default.
• W2551930064 hasConceptScore W2551930064C86803240 @default.
• W2551930064 hasConceptScore W2551930064C98274493 @default.
• W2551930064 hasLocation W25519300641 @default.
• W2551930064 hasOpenAccess W2551930064 @default.
• W2551930064 hasPrimaryLocation W25519300641 @default.
• W2551930064 hasRelatedWork W1575204077 @default.
• W2551930064 hasRelatedWork W1986491356 @default.
• W2551930064 hasRelatedWork W1986880818 @default.
• W2551930064 hasRelatedWork W1990705108 @default.
• W2551930064 hasRelatedWork W1992778132 @default.
• W2551930064 hasRelatedWork W2004611844 @default.
• W2551930064 hasRelatedWork W2006774383 @default.
• W2551930064 hasRelatedWork W2008711099 @default.
• W2551930064 hasRelatedWork W2048598890 @default.
• W2551930064 hasRelatedWork W2072950603 @default.
• W2551930064 hasRelatedWork W2125211913 @default.
• W2551930064 hasRelatedWork W2134568817 @default.
• W2551930064 hasRelatedWork W2209836101 @default.
• W2551930064 hasRelatedWork W2293821613 @default.
• W2551930064 hasRelatedWork W2555789082 @default.
• W2551930064 hasRelatedWork W2556179041 @default.
• W2551930064 hasRelatedWork W2561245808 @default.
• W2551930064 hasRelatedWork W2562314043 @default.
• W2551930064 hasRelatedWork W2580760784 @default.
• W2551930064 hasRelatedWork W3128970870 @default.
• W2551930064 isParatext "false" @default.
• W2551930064 isRetracted "false" @default.
• W2551930064 magId "2551930064" @default.
• W2551930064 workType "article" @default.